

Commentary on *the Langerhans Cell in Contact Hypersensitivity*

Nicholas A. Soter, M.D.

The origin and function of Langerhans cells remained elusive for many years after their discovery by Paul Langerhans in 1868. It was not until 1961 that an ultrastructural marker of Langerhans cells in the form of a unique organelle was described [1]. Subsequently, while conducting an electron-microscope study of contact allergic reactions in humans [2], Dr. Inga Silberberg-Sinakin and her colleagues noted apposition of lymphocytes to Langerhans cells, suggesting a role for Langerhans cells in immunologic reactions. This paper summarizes an interview with Drs. Inga Silberberg-Sinakin and Rudolf Baer early in 1988, discussing their reminiscences concerning this seminal observation and its implications for Langerhans cell research.

During her early studies of the topical application of mercuric chloride in humans, Dr. Silberberg-Sinakin observed that there was apposition of lymphocyte-like cells to Langerhans cells in the epidermis of individuals with contact allergic reactions but not of those individuals with irritant reactions or of normal subjects [2]. She remembers that it was a troublesome finding to evaluate because findings observed on electron microscopy are difficult to statistically quantitate. Therefore, she proceeded to study a variety of contact allergens in humans [3] and to seek and exploit an animal model [4]. In studies of guinea pigs sensitized to dinitrochlorobenzene (DNCB), subsequent passive transfer experiments with a time-course analysis demonstrated Langerhans cells in dermal lymphatics [5,6], a finding that strengthened the interpretation of an immunologic role for the Langerhans cell.

At that time, very little was known about the biologic functions of the Langerhans cell. As background, Dr. Baer recalled that as early as 1875, Ranvier speculated that Langerhans cells were derived from lymphocytes. However, subsequent informed opinion was that Langerhans cells were effete melanocytes. Then it was recognized that Langerhans cells could be identified by electron microscopy based on the key feature of a distinctive cytoplasmic organelle [1], that the cell membrane of Langerhans cells contained ATPase [7]; and that Langerhans cell granules were endocytotic organelles [8].

Dr. Silberberg-Sinakin went on to say that the initial recognition of the morphologic observations led her and her collaborators at New York University School of Medicine (Dr. Jeanette Thorbecke and Dr. Baer) to suggest that the Langerhans cell was the potential antigen-presenting cell in the skin that people had been seeking. Dr. Silberberg-Sinakin added her perspective on the controversies involved in the acceptance of this work. She stated that there was support within the Department of Dermatology at New York University School of Medicine and among immunologists and cell biologists. Within the general dermatologic community, however, there was reluctance to accept this new immunologic function of the Langerhans cell.

Both Dr. Silberberg-Sinakin and Dr. Baer went on to state that the studies which involved the uptake of ferritin by Langerhans cells and their migration through dermal lymph vessels to the lymph node were not only of great importance in elucidating the fate of antigens taken up in the epidermis and how they migrate to the regional lymph nodes [9,10], but also was the first work that showed a applicability to contact allergy [11]. Although contact allergy has been a model for studying the fate of many different kinds of antigens, it also suggested that in delayed-type hypersensitivity, reactions in general Langerhans cells could serve the same functions. Presumably, larger molecules, such as tumor antigens and microbial antigens such as viruses and fungal antigens, are taken up by Langerhans cells [12]. This function also applies to transplantation antigens, and it has been shown that Langerhans cells play a role in graft rejection [13] in the skin. Moreover, Langerhans cells could be target cells [14], and the damaging effects could be caused by lymphocytes or immune complexes plus complement [14]. In addition, certain physical agents and substances are capable of depressing the functional capacity of Langerhans cells [15–19]; notably ultraviolet A and ultraviolet B and the topical or systemic administration of glucocorticosteroids [20]. There are also different numbers of Langerhans cells in various skin sites. Areas with diminished numbers of Langerhans cells are not able to mount contact reactions [21].

After the observation that Langerhans cells were antigen-bearing cells, Dr. Silberberg-Sinakin said that she and her colleagues reviewed the literature on antigen-bearing or antigen-presenting cells (such as indeterminant dendritic cells, interdigitating reticular cells, follicular dendritic reticular cells described by Nossal, and dendritic cells described by Steinman and Cohn) in other organs such as lymph node,

Department of Dermatology, New York University School of Medicine, New York, New York, U.S.A.

Reprint requests to: Nicholas A. Soter, M.D., Department of Dermatology, New York University School of Medicine, New York, New York 10016.

spleen, and thymus and postulated that some of these cells could be relatives of each other and that knowledge of one cell type may be applicable to others [22]. Dr. Baer concurred that there have been developments in the role of dendritic cells in other organs so that today one can talk about a dendritic cell system. The dendritic cells in lymph nodes, thymus, spleen, Kupffer's cells in the liver, and veil cells in the intestines, are all parts of a large system of dendritic cells [22]. The question has arisen as to whether some of these cells are derived from Langerhans cells. It has been shown [23] that cultured Langerhans cells go through certain maturational transformations and that they resemble lymphoid dendritic cells, suggesting that the maturation of stimulatory function within the dendritic cell lineage represents an important control point in the induction phase of cell-mediated immunity. Apparently, all of these dendritic cells have the capacity to present antigens, and they are much better at this than cells of the macrophage-monocytes series, he added. Depending on the site in which these dendritic cells are located, there are certain differences; however, they are at poor phagocytes and good at pinocytosis and endocytosis. What is termed processing antigens is actually the endocytosis of these particles [24,25] followed by processing them chemically and returning them to the surface. The Langerhans cell is the foremost type of dendritic cell involved in this function, he said.

Dr. Baer went on to say that, regarding clinical application, there is now an increasing interest in aging, and that the demonstration of the waning immunologic capacity of human beings as they get older, at least in part, may be due to fewer Langerhans cells. There seems to be a decrease in Langerhans cells in older humans [26]. Moreover, there is evidence that there is a difference in the number of functioning Langerhans cells between young and old mice [27].

Dr. Baer said that there were some very basic things that are still in a primitive state of knowledge. For example, it is not known whether Langerhans cells are one particular cell line or whether there are different varieties with, perhaps, different functions. An important development arising from the Langerhans cell studies is that another dendritic cell has been discovered known as the Thy 1⁺ cell. Although this cell only has been found in mice to date [28–30], there is most certainly an equivalent in human beings and in other species. These Thy 1⁺ cells are important because they may be the antigen-presenting cells for suppressor cells, in contrast to the Ia⁺ Langerhans cells [31–33], which are the antigen-presenting cells for CD₄⁺ T cells and for delayed-type hypersensitivity.

Dr. Baer went on to say that after it became evident that CD₄⁺ T cells were destroyed by the human immunodeficiency virus (HIV), it was shown that the number of epidermal Langerhans cells in cutaneous biopsy specimens from patients with acquired immunodeficiency syndrome (AIDS), AIDS-related complex (ARC), and high-risk patients who had no evidence of AIDS or ARC [34], as assessed by examination of Ia antigens and membrane ATPase, was diminished. A possible reason for the observation that

Langerhans cells are effected in AIDS may be that Langerhans cells also have the CD4 (T4) receptor [35,36]. The HIV virus enters the T cells by attaching to the CD4 receptor [37,38], suggesting that the virus also can enter the Langerhans cells via this receptor. He concluded that a major impact of the research on the Langerhans cell has been on the general knowledge about the skin. This includes the recognition that the skin is a major immunologic organ and the fact that the Langerhans cell is one of the features that seems to make it so.

REFERENCES

1. Birbeck MS, Breathnach AS, Everall JD: An electron microscope study of basal melanocytes and high-level clear cells (Langerhans cells) in vitiligo. *J Invest Dermatol* 37:51–64, 1961
2. Silberberg I: Studies by electron microscopy of epidermis after topical application of mercuric chloride. Morphologic and histochemical findings in epidermal cells of human subjects who do not show allergic sensitivity or primary irritant reactions to mercuric chloride (0.1%). *J Invest Dermatol* 56:147–160, 1971
3. Silberberg I: Apposition of mononuclear cells to Langerhans cells in contact allergic reactions. An ultrastructural study. *Acta Derm Venereol (Stockh)* 53:1–12, 1973
4. Silberberg I, Baer RL, Rosenthal SA: The role of Langerhans cells in contact allergy. I. An ultrastructural study in actively induced contact dermatitis in guinea pigs. *Acta Derm Venereol (Stockh)* 54:321–331, 1974
5. Silberberg I, Baer RL, Rosenthal SA, Thorbecke GJ, Berezowsky V: Dermal and intravascular Langerhans cells at sites of passively induced allergic contact sensitivity. *Cell Immunol* 18:435–453, 1975
6. Silberberg I, Baer RL, Rosenthal SA: Circulating Langerhans cells in a dermal vessel. *Acta Derm Venereol (Stockh)* 54:81–86, 1974
7. Wolff K, Winkelmann RK: Quantitative studies on the Langerhans cell population of guinea pig epidermis. *J Invest Dermatol* 48:504–513, 1967
8. Hashimoto K: Langerhans' cell granule. An endocytotic organelle. *Arch Dermatol* 104:148–160, 1971
9. Silberberg-Sinakin I, Thorbecke GJ, Baer RL, Rosenthal SA, Berezowski V: Antigen-bearing Langerhans cells in skin, dermal lymphatics and in lymph nodes. *Cell Immunol* 25:137–151, 1976
10. Silberberg-Sinakin I, Baer RL, Thorbecke GJ: Langerhans cells: a review of their nature with emphasis on their immunologic functions. *Prog Allergy* 24:268–294, 1978
11. Silberberg I, Baer RL, Rosenthal SA: The role of Langerhans cells in allergic contact hypersensitivity: a review of findings in man and guinea pigs. *J Invest Dermatol* 66:210–217, 1976
12. Braathen LR, Berle E, Mobeck-Hanssen U, Thorsby E: Studies on human epidermal Langerhans cells. II. Activation of human T lymphocytes to herpes simplex virus. *Acta Derm Venereol (Stockh)* 60:381–387, 1980
13. Daynes RA, Spellman CW, Woodward JG, Stewart DA: Studies into the transplantation biology of ultraviolet light-induced tumors. *Transplantation* 23:343–348, 1977
14. Silberberg-Sinakin I, Fedorko ME, Baer RL, Rosenthal SA, Berezowsky V, Thorbecke GJ: Langerhans cells: target cells in immune complex reactions. *Cell Immunol* 32:400–416, 1977
15. Stingl G, Gazze-Stingl LA, Aberer W, Wolff K: Antigen presentation by murine epidermal Langerhans cells and its alteration by ultraviolet B light. *J Immunol* 127:1707–1713, 1981
16. Stingl LA, Sauder DN, Iijima M, Wolff K, Pehamberger H, Stingl G: Mechanism of UV-B-induced impairment of the antigen-presenting capacity of murine epidermal cells. *J Immunol* 130:1586–1591, 1983
17. Bergstresser PR, Toews GB, Streilein JW: Natural and perturbed distributions of Langerhans cells: responses to ultraviolet light, heterotopic skin grafting, and dinitrofluorobenzene sensitization. *J Invest Dermatol* 75:73–77, 1980

18. Greene MI, Sy MS, Kripke M, Benacerraf B: Impairment of antigen-presenting cell function by ultraviolet radiation. *Proc Natl Acad Sci (USA)* 76:6591-6595, 1979
19. Aberer W, Schuler G, Stingl G, Hönigsmann H, Wolff K: Ultraviolet light depletes surface markers of Langerhans cells. *J Invest Dermatol* 76:202-210, 1981
20. Belsito DV, Flotte TJ, Lim HW, Baer RL, Thorbecke GJ, Gigli I: Effects of glucocorticosteroids on epidermal Langerhans cells. *J Exp Med* 155:291-302, 1982
21. Toews GB, Bergstresser PR, Streilein JW: Epidermal Langerhans cell density determines whether contact sensitivity or unresponsiveness follows skin painting with DNFB. *J Immunol* 124:445-453, 1980
22. Silberberg-Sinakin I, Thorbecke GJ: The Langerhans Cell. In: Carr I, Daems WT (eds.). *The Reticuloendothelial System*, Vol 1. New York, Plenum, 1980, pp 555-605
23. Inaba K, Schuler G, Witmer MD, Valinsky J, Atassi B, Steinman R: Immunologic properties of purified Langerhans cells: distinct requirements for stimulation of unprimed and sensitized T lymphocytes. *J Exp Med* 164:605-613, 1986
24. Takigawa M, Iwatsuki K, Yamada M, Okamoto H, Imamura S: The Langerhans cell granule is an adsorptive endocytic organelle. *J Invest Dermatol* 85:12-15, 1985
25. Hanau D, Fabre M, Schmitt DA, Garaud J-C, Pauly G, Tongio M-M, Mayer S, Cazenave J-P: Human epidermal Langerhans cells cointernalize by receptor-mediated endocytosis "nonclassical" major histocompatibility complex class I molecules (T6 antigens) and class II molecules (HLA-DR antigens). *Proc Nat Acad Sci (USA)* 84:2901-2905, 1987
26. Gilchrist BA, Murphy GF, Soter NA: Effect of chronologic aging and ultraviolet irradiation on Langerhans cells in human epidermis. *J Invest Dermatol* 79:85-88, 1982
27. Belsito DV, Dersarkissian RM, Thorbecke GJ, Baer RL: Reversal by lymphokines of the age-related hyporesponsiveness to contact sensitization and reduced Ia expression on Langerhans cells. *Arch Dermatol Res* 279:s76-s80, 1987
28. Bergstresser PR, Tigelaar RE, Dees JH, Streilein JW: Thy-1 antigen-bearing dendritic cells populate murine epidermis. *J Invest Dermatol* 81:286-288, 1983
29. Sullivan S, Bergstresser PR, Tigelaar RE, Streilein JW: Induction and regulation of contact hypersensitivity by resident, bone marrow-derived, dendritic epidermal cells: Langerhans cells and Thy-1 + epidermal cells. *J Immunol* 137:2460-2467, 1986
30. Romani N, Stingl G, Tschachler E, Witmer MD, Steinman RM, Shevach EM, Schuler G: The Thy-1-bearing cell of murine epidermis: a distinctive leukocyte perhaps related to natural killer cells. *J Exp Med* 161:1368-1383, 1985
31. Stingl G, Katz SI, Shevach EM, Wolff-Schreiner E, Green I: Detection of Ia antigens on Langerhans cells in guinea pig skin. *J Immunol* 120:570-578, 1978
32. Forsum U, Klareskog L, Tjernlund UM, Peterson PA: Significance of the expression of HLA-DR antigen on epidermal Langerhans cells. *Acta Derm Venereol (Stockh)* 58(Suppl 79):37-40, 1978
33. Rowden G, Lewis MG, Sullivan AK: Ia antigen expression on human epidermal Langerhans cells. *Nature* 268:247-248, 1977
34. Belsito DV, Sanchez MR, Baer RL, Valentine F, Thorbecke GJ: Reduced Langerhans' cell Ia antigen and ATPase activity in patients with the acquired immunodeficiency syndrome. *N Engl J Med* 310:1279-1282, 1984
35. Wood GS, Warner NL, Warnke RA: Anti-Leu-3/T4 antibodies react with cells of monocyte/macrophage and Langerhans lineage. *J Immunol* 131:212-216, 1983
36. Dagleish AG, Beverley PCL, Clapham PR, Crawford DH, Greaves MF, Weiss RA: The CD4 (T4) antigen is an essential component of the receptor for the AIDS retrovirus (letter). *Nature* 312:763-767, 1984
37. Tschachler E, Groh V, Popovic M, Mann DL, Konrad K, Safai B, Eron L, diMarzo Veronese F, Wolff K, Stingl G: Epidermal Langerhans cells—a target for HTLV-III/LAV infection. *J Invest Dermatol* 88:233-237, 1987
38. Tschachler E, Groh V, Rappersberger K, Gardner S, Popovic M, Schenk P, Konrad K, Mann DL, Wolff K, Stingl G: Epidermal Langerhans cells (LC)—a virus reservoir in HIV infection. *J Invest Dermatol* 88:522, 1987